Retatrutide: The Real Reason It May Outperform Every Other Peptide

Retatrutide is being called the next Ozempic, but that framing misses what actually makes this peptide different. In this breakdown, Dr. Moeller explains why retatrutide may outperform every other GLP-1 therapy on the market by targeting a third receptor, glucagon, in addition to GLP-1 and GIP. Learn the mechanism, the latest phase 3 trial data, the muscle loss conversation, side effects, and what this triple agonist could mean for the future of obesity medicine and metabolic health. ===================TIME STAMPS===================== 00:00 Why Retatrutide May Outperform Ozempic 01:12 How Retatrutide Works In The Body 02:21 The Glucagon Receptor Difference 06:37 Phase 2 And Phase 3 Trial Results 10:28 Weight Loss Versus Muscle Loss 16:00 Retatrutide Side Effects To Watch 17:45 FDA Approval And What Comes Next ______________________Support The Channel__________________________ My Linktree ➢https://linktr.ee/dr.michaelmoeller ———————————————— Lets Connect———————————————— 📺 Click here to Subscribe:    / @drmichaelmoeller   🔴========================⚠️ Full Disclaimer⚠️========================🔴 MEDICAL DISCLAIMER: This video is for general information and educational purposes only and does not constitute the practice of medicine, the giving of medical advice, or the establishment of a doctor-patient relationship. The information provided is NOT intended to be a substitute for professional medical advice, diagnosis, or treatment, and is NOT intended to treat, diagnose, cure, or prevent any disease or medical condition. Always seek the guidance of your physician or qualified healthcare provider with any questions you may have regarding a medical condition. Do not delay or disregard seeking professional medical advice based on anything contained in this video. Do not make any changes to your health regimen, medications, or supplements without first consulting your physician or healthcare provider. Dr. Michael Moeller assumes no liability for any direct or indirect losses, damages, or adverse outcomes that may result from use of the information in this video. All content is provided for educational purposes only and is subject to change without notice. #Retatrutide #glp1 #peptidetherapy